We previously found that 3,9-bis(N,N-dimethylcarbamoyloxy)-5H- benzofuro[3,2-c]
quinoline-6-one (KCA-098) inhibited
bone resorption in organ culture. In this study, to determine if
KCA-098 is therapeutically applicable for the treatment of
osteoporosis, we compared the effect of
KCA-098 on bone tissues with that of
ipriflavone, a
drug that is clinically used for the treatment of
osteoporosis. Both
KCA-098 and
ipriflavone inhibited
parathyroid hormone-,
prostaglandin E2-, 1 alpha,25-dihydroxyvitamin D3- and
interleukin 1 beta-induced
bone resorption of fetal rat bones, but the inhibitory activity of
KCA-098 was more potent than that of
ipriflavone. In fact, the effective concentrations of
KCA-098 were 10 to 100 times lower than those of
ipriflavone.
Oral administration of
KCA-098 (1 and 3 mg/kg) or
ipriflavone (100 mg/kg) to ovariectomized rats on a low-
calcium diet increased the breaking force and bone density of the femora, indicating that
KCA-098 is an effective on the whole animal as
ipriflavone. Furthermore,
KCA-098 increased the length and
calcium content of 9-day chick embryonic femora cultured in vitro, whereas
ipriflavone did not, suggesting that
KCA-098 had a direct stimulatory effect on bone mineralization. Therefore,
KCA-098 seems to be more potent than
ipriflavone in stimulating bone tissue formation and may thus be expected to become a useful agent for the treatment of
osteoporosis.